Cargando…

Alzheimer's disease drug development pipeline: 2020

INTRODUCTION: Alzheimer's disease (AD) is a growing public health concern affecting millions of patients worldwide and costing billions of dollars annually. We review the pipeline of drugs and biologics in clinical trials for the treatment of AD. We use the Common Alzheimer's and Related D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cummings, Jeffrey, Lee, Garam, Ritter, Aaron, Sabbagh, Marwan, Zhong, Kate
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7364858/ https://www.ncbi.nlm.nih.gov/pubmed/32695874 http://dx.doi.org/10.1002/trc2.12050

Ejemplares similares

Alzheimer's disease drug development pipeline: 2019
por: Cummings, Jeffrey, et al.
Publicado: (2019)

Alzheimer's disease drug development pipeline: 2018
por: Cummings, Jeffrey, et al.
Publicado: (2018)

Alzheimer's disease drug development pipeline: 2017
por: Cummings, Jeffrey, et al.
Publicado: (2017)

Alzheimer's disease drug development pipeline: 2021
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Alzheimer's disease drug development pipeline: 2023
por: Cummings, Jeffrey, et al.
Publicado: (2023)

Repurposed agents in the Alzheimer’s disease drug development pipeline
por: Bauzon, Justin, et al.
Publicado: (2020)

Alzheimer's disease drug development pipeline: 2022
por: Cummings, Jeffrey, et al.
Publicado: (2022)

Alzheimer's drug-development pipeline: 2016
por: Cummings, Jeffrey, et al.
Publicado: (2016)

Correction: Repurposed agents in the Alzheimer’s disease drug development pipeline
por: Bauzon, Justin, et al.
Publicado: (2023)

Alzheimer’s Disease Drug Development Pipeline 2020
por: Sabbagh, M.N.
Publicado: (2020)

Alzheimer’s disease drug-development pipeline: few candidates, frequent failures
por: Cummings, Jeffrey L, et al.
Publicado: (2014)

Who funds Alzheimer's disease drug development?
por: Cummings, Jeffrey, et al.
Publicado: (2021)

Clinical Trials for Disease-Modifying Therapies in Alzheimer’s Disease: A Primer, Lessons Learned, and a Blueprint for the Future(1)
por: Cummings, Jeffrey, et al.
Publicado: (2018)

Progressive cholinergic decline in Alzheimer's Disease: consideration for treatment with donepezil 23 mg in patients with moderate to severe symptomatology
por: Sabbagh, Marwan, et al.
Publicado: (2011)

MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients with Mild Cognitive Impairment Due to Alzheimer’s Disease
por: Decourt, Boris, et al.
Publicado: (2020)

Fluid Biomarkers in Clinical Trials of Alzheimer’s Disease Therapeutics
por: Ritter, Aaron, et al.
Publicado: (2015)

Erratum: Alzheimer's disease drug development pipeline: 2023
Publicado: (2023)

FDA position statement “Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry”
por: Sabbagh, Marwan N., et al.
Publicado: (2019)

The Cause of Alzheimer’s Disease: The Theory of Multipathology Convergence to Chronic Neuronal Stress
por: Decourt, Boris, et al.
Publicado: (2022)

Neuroscience learning from longitudinal cohort studies of Alzheimer's disease: Lessons for disease-modifying drug programs and an introduction to the Center for Neurodegeneration and Translational Neuroscience
por: Ritter, Aaron, et al.
Publicado: (2018)

Does Informant-Based Reporting of Cognitive Decline Correlate with Age-Adjusted Hippocampal Volume in Mild Cognitive Impairment and Alzheimer’s Disease?
por: Sabbagh, Marwan, et al.
Publicado: (2021)

New Acetylcholinesterase Inhibitors for Alzheimer's Disease
por: Mehta, Mona, et al.
Publicado: (2012)

The “rights” of precision drug development for Alzheimer’s disease
por: Cummings, Jeffrey, et al.
Publicado: (2019)

The Alzheimer’s disease drug development landscape
por: van Bokhoven, Pieter, et al.
Publicado: (2021)

Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer’s disease: analysis of effects of baseline features on treatment response
por: Sabbagh, Marwan, et al.
Publicado: (2013)

Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2020
por: McFarthing, Kevin, et al.
Publicado: (2020)

The price of progress: Funding and financing Alzheimer's disease drug development
por: Cummings, Jeffrey, et al.
Publicado: (2018)

Globalization of Alzheimer's disease clinical trials
por: Cummings, Jeffrey, et al.
Publicado: (2011)

Peripheral Biomarkers for Alzheimer’s Disease: Update and Progress
por: Sabbagh, Marwan N., et al.
Publicado: (2019)

Does taking statins affect the pathological burden in autopsy-confirmed Alzheimer’s dementia?
por: Crum, Jana, et al.
Publicado: (2018)

Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: evaluating the impact of baseline severity
por: Ferris, Steven, et al.
Publicado: (2013)

Effect of TTP488 in patients with mild to moderate Alzheimer’s disease
por: Burstein, Aaron H, et al.
Publicado: (2014)

Open Peer Commentary to “Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019”
por: Sabbagh, Marwan Noel, et al.
Publicado: (2020)

Broader Considerations of Higher Doses of Donepezil in the Treatment of Mild, Moderate, and Severe Alzheimer's Disease
por: Berk, Camryn, et al.
Publicado: (2012)

Novel Therapeutics in Alzheimer's Disease
por: Sabbagh, Marwan, et al.
Publicado: (2012)

2020–2021 Drug Updates: Investigational Therapeutics in the Pipeline
por: Moore, Donald C.
Publicado: (2022)

Editorial Introduction to the Special Issue from the International Symposium on Biomarkers for Alzheimer’s Disease and Related Disorders
por: Sabbagh, Marwan N.
Publicado: (2017)

The development of an automated machine learning pipeline for the detection of Alzheimer’s Disease
por: Chedid, Nicholas, et al.
Publicado: (2022)

Potential Peripheral Biomarkers for the Diagnosis of Alzheimer's Disease
por: Patel, Seema, et al.
Publicado: (2011)

Alzheimer’s disease beyond amyloid: strategies for future therapeutic interventions
por: Shi, Jiong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fa27j6112q5agl6mf9kisa17cg